Natera, Inc. - NTRA STOCK NEWS

Natera, based in Austin, Texas, responded strongly to a report by Hindenburg Research, labeling it misleading and an attempt by short sellers to profit from negative sentiments. The company emphasizes its commitment to compliance and the efficacy of its testing procedures, supported by over 100 peer-reviewed studies involving more than 1.3 million patients. Natera highlights its high performance in recent studies and maintains an A+ BBB rating, demonstrating a focus on patient satisfaction and operational integrity.

Natera, Inc. (NTRA) reported Q4 2021 revenues of $173.0 million, a 53.9% increase year-over-year, with full-year revenues reaching $625.5 million, up 60%. Product revenues rose 51.1% in Q4, driven by a 48.7% increase in tests processed. However, total operating expenses surged 72.8% in Q4, leading to a net loss of $140.6 million or ($1.48) per share. The company holds $914.5 million in cash, forecasting 2022 revenues between $770 million and $790 million with an approximate gross margin of 46% to 48%.

Natera, Inc. (NASDAQ: NTRA) announced it will release its fourth quarter and year-end 2021 financial results on February 24, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and financial outlook. Natera is a leader in cell-free DNA testing, focused on oncology, women's health, and organ health. Their tests are backed by over 100 peer-reviewed publications, ensuring high accuracy, with operations in Texas and California.

Natera, Inc. (NASDAQ: NTRA) announced the results of a large real-world study confirming the effectiveness of its Prospera donor-derived cell-free DNA (dd-cfDNA) test for kidney transplant patients. Conducted across 33 clinics with 879 patients, the study reported a 64% positive predictive value in detecting active rejection among those with high-risk results. The findings, published in Transplantation Proceedings, indicate that dd-cfDNA testing can enhance physician decision-making in managing transplant patients. This adds to existing evidence supporting the Prospera test's clinical utility.

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, will present updates at several upcoming investor conferences. CEO Steve Chapman and CFO Mike Brophy will speak at:

• 11th Annual SVB Leerink Global Health Care Conference on February 16, 2022, at 1:00 p.m. ET
• Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:50 p.m. ET
• Raymond James 43rd Annual Institutional Investors Conference on March 9, 2022, at 8:40 a.m. ET

Webcasts can be accessed at investor.natera.com.

Natera, Inc. (NASDAQ: NTRA) has announced significant findings from the CIRCULATE-Japan trial concerning its Signatera test for colorectal cancer (CRC). The study involved over 3,000 CRC patients, with key results presented at the ASCO GI 2022 conference. Notably, MRD-positive patients saw substantial benefits from adjuvant chemotherapy, while MRD-negative patients did not. The study also highlighted a 67.6% sensitivity of the Signatera test in detecting cancer recurrences. These results may influence future treatment guidelines for CRC.

Natera, Inc. (NASDAQ: NTRA) announced the publication of the groundbreaking SMART study in the American Journal of Obstetrics and Gynecology, demonstrating the efficacy of its non-invasive prenatal testing (NIPT) for detecting 22q11.2 deletion syndrome (22q11.2DS). Enrolling over 20,000 patients globally, the study reveals a prevalence of 1 in 1,524 pregnancies, with Panorama detecting all common cases and achieving a low false positive rate of 0.05%. This supports the expansion of routine prenatal screening to include 22q11.2DS, emphasizing the need for diagnostic follow-ups.

Natera, Inc. (NASDAQ: NTRA) announced new data presentations at the ASCO GI Symposium from January 20-22, 2022, concerning its tumor-informed molecular residual disease test, Signatera. Highlighted studies include two oral presentations and four posters focusing on colorectal, pancreatic, and anal cancers. One study shows how MRD testing can predict treatment benefits for colorectal cancer patients post-surgery. An investor call reviewing the ASCO GI results is scheduled for January 24, 2022, at 1:30 PM PT.

Natera, Inc. (NASDAQ: NTRA) has announced the appointment of Dr. Alexey Aleshin as General Manager of Early Cancer Detection (ECD), part of its strategic expansion into the ECD market. Dr. Aleshin, who has extensive experience in oncology, will continue overseeing medical affairs while leading ECD initiatives. The company aims to leverage a biobank of colorectal cancer samples from Aarhus University, potentially accelerating ECD product development and FDA approval. CEO Steve Chapman emphasizes the opportunity to improve early cancer detection, enhancing patient outcomes.